Evidence map›Paper›PMID 30718264›Full record

ArticleBMJ case reports2019

Adalimumab-induced acute myeloid leukaemia in a patient with Crohn's disease.

Talal Alzahrani, Abdulelah Nuqali, Nejat Naser, Amar R Jariwala

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Talal AlzahraniDepartment of Medicine, The George Washington University, Washington, District of Columbia, USA.
Abdulelah NuqaliDepartment of Medicine, The George Washington University, Washington, District of Columbia, USA.
Nejat NaserDepartment of Medicine, The George Washington University, Washington, District of Columbia, USA.
Amar R JariwalaDepartment of Pathology, The George Washington University, Washington, District of Columbia, USA.
George Washington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a patient with Crohn's disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.

Indexed as

AdalimumabAdultAntirheumatic AgentsBone MarrowChemotherapy-Induced Febrile NeutropeniaConsolidation ChemotherapyCore Binding Factor beta SubunitCrohn DiseaseGene RearrangementHumansInduction ChemotherapyLeukemia, Myeloid, AcuteMaleRemission InductionAdalimumabAntirheumatic AgentsCore Binding Factor beta Subunitcrohn’s diseasehaematology (drugs and medicines)

Identifiers

PMID30718264
PMCPMC6366805
OpenAlexW2914256786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.